Precision oncology drugs have significant unrealized revenue potential because of current inefficiencies in the diagnostic pathway. This is according to Peter Keeling, CEO of Diaceutics, who told the Pink Sheet that pharma companies could “double” the lifecycle revenue generated by a precision cancer drug in return for higher investment in companion diagnostics (CDx).
The patient benefits of precision medicine are well documented, Keeling said, but the testing infrastructure “has had no real champions and the investment to fix this is above the budget...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?